<p>Groups of C57BL/6 mice were i.n treated with either clodronate-liposomes to deplete alveolar macrophages or PBS-liposomes as treatment controls. Twenty-four hours later, all mice were i.n infected with 1×10<sup>8</sup> CFU of freshly cultured <i>A. baumannii</i>. Five mice from each group were euthanized at 4, 24, 48 and 72 h after the infection. The bacterial burdens in the lung, BAL fluid, and spleen were determined by quantitative bacterial culture. Dashed line indicates lower limit of detection (1.3 log<sub>10</sub>). Data are presented as mean ± SD (n = 5). **P<0.01.</p
Acinetobacter baumannii is an emerging bacterial pathogen that causes nosocomial pneumonia and other...
Indirect evidence suggests that innate immune mechanisms involving alveolar macrophages (AMs) are of...
The objective of this study was to evaluate the role of alveolar macrophages (AM) in clearance of P...
<p>Groups of C57BL/6 mice were i.n. treated with either clodronate-liposomes to deplete alveolar mac...
<p>Groups of C57BL/6 mice (n = 5 per group) were i.n. inoculated with 10<sup>8</sup> CFU of freshly ...
<p>Twelve groups of BALB/c mice (n = 3–9) were infected by the i.v. route with four different strain...
<p>(<b>A</b>) C57BL/6J mice were treated with clodronate- or PBS-loaded liposomes for 24 hours. Mice...
<p>C57BL/6 mice were i.n. inoculated with 10<sup>8</sup> CFU of freshly cultured <i>A. baumannii</i>...
This study aimed to evaluate the role of alveolar macrophages (AMs) in the internalisation and early...
<p>(A–E) Mice were treated with clodronate or control PBS liposomes 2 days prior to infection with 5...
In 2017, the WHO identified Acinetobacter baumannii as the top priority for the development of new a...
<p>A) Determination of the LD<sub>50</sub> of <i>A. baumannii</i> ATCC 17978. Groups of 5 mice were ...
<p>Groups of C57BL/6 mice were i.n. inoculated with 10<sup>8</sup> CFU of freshly cultured <i>A. bau...
<p>Groups of 4 C57BL/6 mice were infected with either 10<sup>3</sup> or 10<sup>6</sup> NMII. Prior t...
Acinetobacter baumannii is an emerging bacterial pathogen that causes nosocomial pneumonia and other...
Acinetobacter baumannii is an emerging bacterial pathogen that causes nosocomial pneumonia and other...
Indirect evidence suggests that innate immune mechanisms involving alveolar macrophages (AMs) are of...
The objective of this study was to evaluate the role of alveolar macrophages (AM) in clearance of P...
<p>Groups of C57BL/6 mice were i.n. treated with either clodronate-liposomes to deplete alveolar mac...
<p>Groups of C57BL/6 mice (n = 5 per group) were i.n. inoculated with 10<sup>8</sup> CFU of freshly ...
<p>Twelve groups of BALB/c mice (n = 3–9) were infected by the i.v. route with four different strain...
<p>(<b>A</b>) C57BL/6J mice were treated with clodronate- or PBS-loaded liposomes for 24 hours. Mice...
<p>C57BL/6 mice were i.n. inoculated with 10<sup>8</sup> CFU of freshly cultured <i>A. baumannii</i>...
This study aimed to evaluate the role of alveolar macrophages (AMs) in the internalisation and early...
<p>(A–E) Mice were treated with clodronate or control PBS liposomes 2 days prior to infection with 5...
In 2017, the WHO identified Acinetobacter baumannii as the top priority for the development of new a...
<p>A) Determination of the LD<sub>50</sub> of <i>A. baumannii</i> ATCC 17978. Groups of 5 mice were ...
<p>Groups of C57BL/6 mice were i.n. inoculated with 10<sup>8</sup> CFU of freshly cultured <i>A. bau...
<p>Groups of 4 C57BL/6 mice were infected with either 10<sup>3</sup> or 10<sup>6</sup> NMII. Prior t...
Acinetobacter baumannii is an emerging bacterial pathogen that causes nosocomial pneumonia and other...
Acinetobacter baumannii is an emerging bacterial pathogen that causes nosocomial pneumonia and other...
Indirect evidence suggests that innate immune mechanisms involving alveolar macrophages (AMs) are of...
The objective of this study was to evaluate the role of alveolar macrophages (AM) in clearance of P...